"Among persons aged ≥50 years who reported homologous mRNA COVID-19 vaccination, injection site and systemic reactions were less frequent after a second booster dose than after the first booster dose. Ninety-five percent of 8,515 events reported to the Vaccine Adverse Event Reporting System were nonserious." - Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
Additional Authors: Phillip G. Blanc, John R. Su, Brandon Hugueley, Casey Parker, Tanya R. Myers, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Resource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.